• DOI:10.1016/j.ando.2013.04.004
Corpus ID: 205516313

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

@article{Kerlan2013UseOI,
  title={Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.},
  author={V. Kerlan and D. Gouet and M. Marre and {\'E}. Renard},
  journal={Annales d'endocrinologie},
  year={2013},
  volume={74 5-6},
  pages={
          487-90
        }
}

V. Kerlan, D. Gouet, +1 author É. Renard

Published 2013

Medicine

Annales d'endocrinologie

Insulin degludec is a new basal insulin analogue with an ultra-long duration of action that provides a flat and stable action profile with a duration of action greater than 42 hours. Two clinical trials comparing insulin degludec and insulin glargine in basal-bolus therapy have recently been published. Both were 52-week, multicentre, randomised (3:1), treat-to-target trials in patients already using insulin. In both type 1 (n=629) and type 2 diabetes (n=1006), insulin degludec was non-inferior… CONTINUE READING

View on PubMed

em-consulte.com

Save to Library

Create Alert

Cite

Launch Research Feed